---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-010655"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:28:52.897235+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences reports FY2022 net loss of $19.3M; advances EB-373 toward Phase 1 in Q4 2023

## Summary
- Comprehensive net loss $19.3M for FY2022 vs $48.8M in FY2021; diluted loss per share $13.00.
- Cash and cash equivalents $17.7M, working capital $14.4M as of Dec. 31, 2022.
- Lead candidate EB-373 nominated from EVM201 Series; Phase 1 trial planned for Q4 2023 in Australia.
- Appointed Kevin Coveney as CFO and Lynn Gallant as VP Clinical Operations during year.

## SEC filing metadata
- accession: 0001493152-23-010655
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315223010655/0001493152-23-010655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315223010655/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-010655
- JSON: https://secwatch.observer/filing/0001493152-23-010655.json
- Plain text: https://secwatch.observer/filing/0001493152-23-010655.txt

## Key facts
- Earnings Releases
  Enveric Biosciences, Inc. reported the fiscal year ended December 31, 2022 results: net income $19.3 million, EPS $13.00.
  - Period: the fiscal year ended December 31, 2022
  - Net income: $19.3 million
  - EPS: $13.00
  - Result: reported results
  source text: Comprehensive net loss was $19.3 million for the year ended December 31, 2022, including $2.4 million in net non-cash expenses, with a basic and diluted loss per share of $13.00
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315223010655/0001493152-23-010655-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.